Cumulative incidence of MACEs, stratified by the presence or absence of new or worsened HTN development among patients treated with ibrutinib. Observed vs predicted cumulative new HTN at 1 year (A) along with the incidence of grade 3 or higher HTN during ibrutinib use in patients without preceding HTN at baseline, 3, 6, 9, and 12 months (B). Data reflect JNC-8 HTN cutoffs of 140/90 mm Hg for comparison to established HTN models.¹⁸